Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

NECT Product Profile - Overview


NECT = Nifurtimox-Eflornithine Combination Therapy

NECT is the first new, improved treatment option in 25 years for stage 2 (advanced stage) human African trypanosomiasis (HAT) also known as sleeping sickness. It consists of a simplified coadministration of nifurtimox, which is given orally, and eflornithine, which is given intravenously.

  • Launched in 2009
  • Included in the Essential Medicines List (EML) of the WHO since 2009
  • Added to the Essential Medicines List for children of the WHO in 2013

  • Much safer than Melarsoprol, a highly toxic, arsenic-based drug that kills 5% of treated patients, still used in 50% of patients.
  • Compared to eflornithine monotherapy, the best previously available treatment for stage 2 HAT, NECT is:
    • As effective
    • Safer
    • Easier to administer
    • More cost-effective
    • Requests shorter hospitalisation
  • The result of a six-year partnership between NGOs, governments, pharmaceutical companies, and the WHO.
  • Donated by Sanofi and Bayer Schering Pharma AG
  • Available in 13 African countries that account for 100% of reported HAT cases
  • Represents 93% of HAT treatments distributed in DRC in 2011

Download NECT dossier in English [PDF 350KB]
Téléchargez le dossier NECT en français [PDF 317KB]
Read more about NECT project

  NECT News
Watch NECT video

On YouTube!
- in English
- en français
Implementation progress
Available in 13 African countries

Request supply signed by Congo and Guinea
Recent Scientific Publications
PLOS NTDs, November 2012
In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness
Clinical Infectious Diseases, October 2012
Combination Therapy (NECT) for second stage gambiense
human African trypanosomiasis: MSF experience in the Democratic Republic of
the Congo

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License